首页 正文

Case report: Personalized, response-adapted neoadjuvant alectinib achieves durable remission in stage IIIB ALK-rearranged lung cancer

{{output}}
Background: Alectinib, a second-generation ALK inhibitor, is established as a first-line treatment for advanced ALK-positive NSCLC and as adjuvant therapy following resection for early-stage disease. However, its role as a neoadj... ...